Resting sympathetic nerve activity is related to age, sex and arterial pressure but not to α2-adrenergic receptor subtype

Journal of Hypertension

Volumn 28, Issue 10, 2010, Pages 2084-2093

  Maqbool, Azhar ^a   West, Robert M ^b   Galloway, Stacey L ^a   Drinkhill, Mark J ^a   Mary, David A S G ^c   Greenwood, John P ^a   Ball, Stephen G ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b Centre for Epidemiology and Biostatistics   (United Kingdom)

^c LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

polymorphism; sympathetic nerve activit

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; RECEPTOR SUBTYPE;

ADULT; ARTERIAL PRESSURE; ARTICLE; AUTONOMIC NERVOUS SYSTEM; BODY MASS; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; ESSENTIAL HYPERTENSION; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE INNERVATION; NEUROGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RECEPTOR GENE; SPECTROPHOTOMETRY; STATISTICAL SIGNIFICANCE; SYMPATHETIC NERVE; SYSTOLIC BLOOD PRESSURE;

EID: 77957288703     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32833c8a36     Document Type: Article

References (67)

1. Anderson EA, Sinkey CA, Lawton WJ, MarkAL. Elevated sympathetic nerve activity in borderline hypertensive humans. Evidence from direct intraneural recordings. Hypertension 1989; 14:177-183.
2. Leimbach WN Jr, Wallin BG, Victor RG, Aylward PE, Sundlof G, MarkAL. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation 1986; 73:913-919.
3. Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 1995; 26:1257-1263.
4. Greenwood JP, Stoker JB, Mary DA. Single-unit sympathetic discharge: quantitative assessment in human hypertensive disease. Circulation 1999; 100:1305-1310.
5. Mancia G, Grassi G, GiannattasioC, Seravalle G. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 1999; 34:724-728.
6. Esler M. The sympathetic system and hypertension. Am J Hypertens 2000; 13:99S-105S.
7. Barretto AC, Santos AC, Munhoz R, Rondon MU, Franco FG, Trombetta IC, et al.Increased muscle sympathetic nerve activity predicts mortalityin heart failure patients. Int J Cardiol 2009; 135:302-307.
8. Schlaich MP, Lambert E, Kaye DM, Krozowski Z, Campbell DJ, Lambert G, et al. Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and Angiotensin neuromodulation. Hypertension 2004; 43:169-175.
9. Mark AL. Regulation of sympathetic nerve activity in mild human hypertension. J Hypertens Suppl. 1990;8:S67-S75.
10. Piascik MT, Soltis EE, Piascik MM, Macmillan LB. Alpha-adrenoceptors and vascular regulation: molecular, pharmacologic and clinical correlates. Pharmacol Ther 1996; 72:215-241.
11. Philipp M, Brede M, Hein L. Physiological significance of alpha(2)-adrenergic receptor subtype diversity: one receptor is not enough. Am J Physiol Regul Integr Comp Physiol 2002; 283:R287-R295.
12. Kirstein SL, Insel PA. Autonomic nervous system pharmacogenomics: a progress report. Pharmacol Rev 2004; 56:31-52.
13. Hein L. Adrenoceptors and signal transduction in neurons. Cell Tissue Res 2006; 326:541-551.
14. Haeusler G. Cardiovascular regulation by central adrenergic mechanisms and its alteration by hypertensive drugs. Circ Res. 1975; 36/37(Suppl 1): 223-232.
15. Langer SZ, Schoemaker H. Alpha-adrenoceptor subtypes in blood vessels: physiology and pharmacology. Clin Exp Hypertens A 1989; 11 (Suppl 1): 21-30.
16. Ruffolo RR, Nichols AJ, Stadel JM, Hieble JP. Pharmacologic and therapeutic applications of alpha 2-adrenoceptor subtypes. Ann Rev Pharmacol Toxicol 1993; 33:243-279.
17. Hein L, Limbird LE, Eglen RM, Kobilka BK. Gene substitution/knockout to delineate the role of alpha 2-adrenoceptor subtypes in mediating central effects of catecholamines and imidazolines. Ann N Y Acad Sci 1999; 881:265-271.
18. Altman JD, Trendelenburg AU, MacMillan L, Bernstein D, Limbird L, Starke K, et al. Abnormal regulation of the sympathetic nervous system in alpha2A-adrenergic receptor knockout mice. Mol Pharmacol 1999; 56:154-161.
19. Kable JW, Murrin LC, Bylund DB. In vivo gene modification elucidates subtype-specific functions of alpha(2)-adrenergic receptors. J Pharmacol Exp Ther 2000; 293:1-7.
20. Bylund DB. Subtypes of alpha 2-adrenoceptors: pharmacological and molecular biological evidence converge. Trends Pharmacol Sci 1988; 9:356-361.
21. Harrison JK, Pearson WR, Lynch KR. Molecular characterization of alpha 1- and alpha 2-adrenoceptors. Trends Pharmacol Sci 1991; 12:62-67.
22. Aantaa R, Marjamaki A, Scheinin M. Molecular pharmacology of alpha 2-adrenoceptor subtypes. Ann Med 1995; 27:439-449.
23. Link RE, Desai K, Hein L, Stevens ME, Chruscinski A, Bernstein D, et al. Cardiovascular regulation in mice lacking alpha2-adrenergic receptor subtypes b and c. Science 1996; 273:803-905.
24. Makaritsis KP, Handy DE, Johns C, Kobilka B, Gavras I, Gavras H. Role of the alpha2B-adrenergic receptor in the development of salt-induced hypertension. Hypertension 1999; 33:14-17.
25. Vayssettes-Courchay C, Bouysset F, Cordi A, Laubie M, Verbeuren TJ. Effects of medullary alpha2-adrenoceptor blockade in the rat. Eur J Pharmacol 2002; 453:287-297.
26. Sivenius K, Niskanen L, Laakso M, Uusitupa M. A deletion in the alpha2B-adrenergic receptor gene and autonomic nervous function in central obesity. Obes Res 2003; 11:962-973.
27. Snapir A, Mikkelsson J, Perola M, Penttila A, Scheinin M, Karhunen PJ. Variation in the alpha2B-adrenoceptor gene as a risk factor for prehospital fatal myocardial infarction and sudden cardiac death. J Am Coll Cardiol 2003; 41:190-194.
28. Masuo K, Katsuya T, Fu Y, Rakugi H, Ogihara T, Tuck ML. Lys418Asn polymorphism of the alpha2-adrenoceptor gene relates to serum uric acid levels but not to insulin sensitivity. Hypertension 2005; 46:144-150.
29. Neumeister A, Charney DS, Belfer I, Geraci M, Holmes C, Sharabi Y, et al. Sympathoneural and adrenomedullary functional effects of alpha2C-adrenoreceptor gene polymorphism in healthy humans. Pharmacogenet Genomics 2005; 15:143-149.
30. Kurnik D, Muszkat M, Friedman EA, Sofowora GG, Diedrich A, Xie HG, et al. Effect of the alpha2C-adrenoreceptor deletion322-325 variant on sympathetic activity and cardiovascular measures in healthy subjects. J Hypertens 2007; 25:763-771.
31. Lockette W, Ghosh S, Farrow S, MacKenzie S, Baker S, Miles P, et al. Alpha 2-adrenergic receptor gene polymorphism and hypertension in blacks. Am J Hypertens 1995; 8:390-394.
32. Luft FC. Molecular genetics of human hypertension. J Hypertens 1998; 16:1871-1878.
33. Dao TT, Kailasam MT, Parmer RJ, Le HV, Le Verge R, Kennedy BP, et al. Expression of altered alpha2-adrenergic phenotypic traits in normotensive humans at genetic risk of hereditary (essential) hypertension. J Hypertens 1998; 16:779-792.
34. Small KM, Forbes SL, Brown KM, Liggett SB. An asn to lys polymorphism in the third intracellular loop of the human alpha 2A-adrenergic receptor imparts enhanced agonist-promoted Gi coupling. J Biol Chem 2000; 275:38518-38523.
35. Rana BK, Insel PA, Payne SH, Abel K, Beutler E, Ziegler MG, et al. Population-based sample reveals gene-gender interactions in blood pressure in white Americans. Hypertension 2007; 49:96-106.
36. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42:1206-1252.
37. Greenwood JP, Scott EM, Stoker JB, Mary DASG. Chronic I1-imidazoline agonism: sympathetic mechanisms in hypertension. Hypertension 2000; 35:1264-1269.
38. Mary DASG, Stoker JB. The activity of single vasoconstrictor nerve units in hypertension. Acta Physiol Scand 2003; 177:367-376.
39. Hogarth AJ, Mackintosh AF, Mary DASG. Gender-related differences in the sympathetic vasoconstrictor drive of normal subjects. Clin Sci (Lond) 2007; 112:353-361.
40. Macefield VG, Wallin BG, Vallbo AB. The discharge behaviour of single vasoconstrictor motoneurones in human muscle nerves. J Physiol (Lond) 1994; 481:799-809.
41. Sundlof G, Wallin BG.The variability of muscle nerve sympathetic activity in resting recumbent man. J Physiol (Lond) 1977; 272:383-397.
42. Flordellis C, Manolis A, Scheinin M, Paris H. Clinical and pharmacological significance of alpha2-adrenoceptor polymorphisms in cardiovascular diseases. Int J Cardiol 2004; 97:367-372.
43. Finley JC Jr, O'Leary M, Wester D, MacKenzie S, Shepard N, Farrow S, et al. A genetic polymorphism of the alpha2-adrenergic receptor increases autonomic responses to stress. J Appl Physiol 2004; 96:2231-2239.
44. Lario S, Calls J, Cases A, Oriola J, Torras A, Rivera F. MspI identifies a biallelic polymorphism in the promoter region of the alpha 2A-adrenergic receptor gene. Clin Genet 1997; 51:129-130.
45. Small KM, Brown KM, Forbes SL, Liggett SB. Polymorphic deletion of three intracellular acidic residues of the alpha 2B-adrenergic receptor decreases G protein-coupled receptor kinase-mediated phosphorylation and desensitization. J Biol Chem 2001; 276:4917-4922.
46. Small KM, Forbes SL, Rahman FF, Bridges KM, Liggett SB. A four amino acid deletion polymorphism in the third intracellular loop ofthe human alpha 2C adrenergic receptor confers impaired coupling to multiple effectors. J Biol Chem 2000; 275:23059-23064.
47. Park L, Nigg JT, Waldman ID, Nummy KA, Huang-Pollock C, Rappley M, et al. Association and linkage of alpha-2A adrenergic receptor gene polymorphisms with childhood ADHD. Mol Psychiatry 2005; 10:572580.
48. Wood SN. Stable and efficient multiple smoothing parameter estimation for generalized additive models. J Am Stat Assoc 2004; 99:673-686.
49. R Development Core Team (2008). R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org.
50. Tank J, Heusser K, Diedrich A, Hering D, Luft FC, Busjahn A, et al. Influence of gender on the interaction between sympathetic nerve activity and central adiposity. J Clin Endocrinol Metab. 2008; 93:4974-4978.
51. Smith PA, Graham LN, Mackintosh AF, Stoker JB, Mary DASG. Relationship between central sympathetic activity and stages of human hypertension. Am J Hypertens 2004; 17:217-222.
52. Wallin BG. Interindividual differences in muscle sympathetic nerve activity: a key to new insight into cardiovascular regulation? Acta Physiol (Oxf) 2007; 190:265-275.
53. Brandfonbrener M, Landowne M, Shock NW. Changes in cardiac output with age. Circulation 1955; 12:557-566.
54. Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Mancia G. Barorefiex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension 1998; 31:68-72.
55. Schlaich MP, Lambert E, Kaye DM, Krozowski Z, Campbell DJ, Lambert G, et al. Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and Angiotensin neuromodulation. Hypertension 2004; 43:169-175.
56. Ebert TJ, Morgan BJ, Barney JA, Denahan T, Smith JJ. Effects of aging on barorefiex regulation of sympathetic activity in humans. Am J Physiol Heart Circ Physiol 1992; 263:H798-H803.
57. Matsukawa T, Sugiyama Y, Mano T. Age-related changes in barorefiex control of heart rate and sympathetic nerve activity in healthy humans. J Auton Nerv Syst 1996; 60:209-212.
58. Smith PA, Meaney JFM, Graham LN, Stoker JB, Mackintosh AF, Mary DASG, Ball SG. Relationship of neurovascular compression to central sympathetic discharge and essential hypertension. J Am Coll Cardiol 2004; 43:1453-1458.
59. Wallin BG, Esler M, Dorward P, Eisenhofer G, Ferrier C, Westerman R, et al. Simultaneous measurements of cardiac noradrenaline spillover and sympathetic outflow to skelet al. muscle in humans. J Physiol (Lond) 1992; 453:45-58.
60. Wallin BG, Thompson JM, Jennings GL, Esler MD. Renal noradrenaline spillover correlates with muscle sympathetic activity in humans. J Physiol 1996; 491:881-887.
61. Alvarez GE, Beske SD, Ballard TP, Davy KP. Sympathetic neural activation in visceral obesity. Circulation 2002; 106:2533-2536.
62. Muntzel MS, Anderson EA, Johnson AK, Mark AL. Mechanisms of insulin action on sympathetic nerve activity. Clin Exp Hypertens 1995; 17:39-50.
63. Dickinson CJ. Cerebral oxidative metabolism in hypertension. Clin Sci (Lond) 1996; 91:539-550.
64. Hogarth AJ, Mackintosh AF, Mary DASG. The effect of gender on sympathetic nerve hyperactivity of essential hypertension. J Human Hypertens 2007; 21:239-245.
65. Lenders JW, Golczynska A, Goldstein DS. Glucocorticoids, sympathetic activity, and presynaptic alpha 2-adrenoceptor function in humans. J Clin Endocrinol Metab 1995; 80:1804-1808.
66. Wenzel RR, Spieker L, Qui S, Shaw S, Luscher TF, Noll G. I1 -imidazoline agonist moxonidine decreases sympathetic nerve activity and blood pressure in hypertensives. Hypertension 1998; 32:1022-1027.
67. Reis DJ, Piletz JE. The imidazoline receptor in control of blood pressure by clonidine and allied drugs. Am J Physiol 1997; 273:R1569-R1571.